Dirvest

3.4 1 vote

Baxter International

About

Global medical products company providing essential therapies for kidney disease, hospital care, and surgical procedures. Over 85 years of healthcare innovation.

Aging Population Stocks

Baxter provides essential therapies for kidney disease, hospital care, and surgical procedures, with over 85 years of healthcare innovation serving aging patient populations.

Key Financials BAX

Price $19.79

Change (1D) +5.77%

Change (30D) +3.56%

Change (60D) +11.37%

Change (90D) -14.51%

Change (180D) -35.28%

Change (1Y) -34.66%

Change (5Y) -74.30%

P/E Ratio 4.95

EPS (TTM) $4.00

52-Week Range $17.40 — $37.74

50-Day MA $19.74

Volume 15.81M

Data updated Feb 15 · Source: Twelve Data

3.4 1 vote

AI Reviews

🤖

Claude Opus 4.6 Anthropic

3.4 /5

Baxter International, a major medical products and renal care company, presents a complex investment case. The stock has suffered a dramatic decline"down 74% over five years and 35% over the past year"reflecting significant operational challenges, debt concerns from the Hill-Rom acquisition, and the recent divestiture of its kidney care segment (Vantive). The remarkably low P/E of 4.95 with EPS of $4.00 suggests either deep value or earnings that may not be sustainable in their current form post-restructuring.

Bull case: Baxter's core hospital products and medication delivery businesses serve essential healthcare needs. The aging population thesis remains intact as elderly patients disproportionately consume hospital supplies, IV solutions, and infusion therapies. At under $20, much bad news appears priced in, and recent 30/60-day momentum suggests stabilization.

Bear case: Heavy debt load, ongoing restructuring risk, and the separation from its kidney care business removes a key aging-population growth driver. The 5-year destruction of shareholder value raises governance concerns. Trading near 52-week lows with the 180-day decline of 35% signals persistent institutional selling.

Baxter offers turnaround potential but carries substantial execution risk.

Category Ratings

Aging Population Stocks

3.4

Feb 15, 2026

AI-Generated Review Generated via Anthropic API. This is an automated evaluation, not a consumer review. Learn more

System Prompt Used:

You are Claude Opus 4.6, an AI stock analyst for Dirvest.com - an investment directory that features curated stock listings with AI-generated reviews. Your task is to write a thoughtful, balanced investment review of the publicly traded company provided.

Guidelines:
- Write an investment-focused review based on what you know about this company and its stock
- Assess the investment thesis: financial health, growth prospects, competitive position, and risks
- If financial data is provided, reference key metrics (valuation, earnings, dividends) in your analysis
- Be balanced: mention both bull and bear cases
- Provide a rating for EACH category the item belongs to (scale 1-5, can include .1 increments like 3.1, 4.8)
- Consider the item's performance/fit within each specific category when giving ratings
- Keep the review between 80-200 words
- Write in a professional, analytical tone suitable for investors


User Prompt: Please review the following:

Name: Baxter International
Website: https://www.baxter.com
Ticker: BAX
Categories: Aging Population Stocks

Market Data:
- Current Price: $19.79 (5.77%)
- Change (30D): 3.56%
- Change (60D): 11.37%
- Change (90D): -14.51%
- Change (180D): -35.28%
- Change (1Y): -34.66%
- Change (5Y): -74.30%
- 52-Week High: $37.74
- 52-Week Low: $17.40
- 50-Day MA: $19.74
- Volume: 15.81M
- P/E Ratio: 4.95
- EPS (TTM): $4.00

Added: Feb 15, 2026

baxter.com

Dirvest

Baxter International

About

Aging Population Stocks

Key Financials BAX

AI Reviews

Category Ratings

Categories

Market insights, delivered